Tags

Type your tag names separated by a space and hit enter

Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Int J Clin Pract. 2005 Dec; 59(12):1377-86.IJ

Abstract

This randomised, double-blind study evaluated the efficacy and safety of ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg tablet compared to doubling the atorvastatin (ATV) dose in hypercholesterolaemic patients with atherosclerotic or coronary heart disease (CHD). The study group included 435 male and female CHD patients (aged >or=18 years) who had not achieved their low-density lipoprotein cholesterol (LDL-C) goal of <2.50 mmol/l while on a stable dose of ATV 10 mg for >or=6 weeks. After a 1-week diet/stabilisation period, patients with LDL-C >or=2.50 mmol/l and <or=4.20 mmol/l were randomised (1:1) to EZE/SIMVA 10/20 mg/day (n = 221) or ATV 20 mg/day (n = 214) for 6 weeks. The primary efficacy objective was to determine the per cent reduction from baseline in LDL-C at week 6. EZE/SIMVA 10/20 mg produced significantly greater mean per cent changes from baseline in LDL-C compared with ATV 20 mg (-32.8 vs. -20.3%; p </= 0.001). A significantly greater proportion of patients achieved an LDL-C goal <2.50 mmol/l with EZE/SIMVA than ATV (77.9 vs. 51.9%; p <or= 0.001). Significant improvements in total cholesterol (-20.3 vs. -13.0%), non-high-density lipoprotein cholesterol (non-HDL-C) (-27.9 vs. -17.0%), apolipoprotein B (-23.4 vs. -14.7%) and HDL-C (1.8 vs. -0.4%) were observed after switching to EZE/SIMVA 10/20 mg for 6 weeks (p < 0.05 for all parameters). EZE/SIMVA 10/20 mg was generally well tolerated, with an overall safety profile similar to that of ATV 20 mg. EZE/SIMVA 10/20 mg produced superior lipid-altering efficacy by dual inhibition of cholesterol synthesis and intestinal absorption compared with doubling the dose of ATV from 10 to 20 mg.

Authors+Show Affiliations

Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain. vbarrios.hrc@salud.madrid.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16351668

Citation

Barrios, V, et al. "Lipid-altering Efficacy of Switching From Atorvastatin 10 Mg/day to Ezetimibe/simvastatin 10/20 Mg/day Compared to Doubling the Dose of Atorvastatin in Hypercholesterolaemic Patients With Atherosclerosis or Coronary Heart Disease." International Journal of Clinical Practice, vol. 59, no. 12, 2005, pp. 1377-86.
Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract. 2005;59(12):1377-86.
Barrios, V., Amabile, N., Paganelli, F., Chen, J. W., Allen, C., Johnson-Levonas, A. O., Massaad, R., & Vandormael, K. (2005). Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. International Journal of Clinical Practice, 59(12), 1377-86.
Barrios V, et al. Lipid-altering Efficacy of Switching From Atorvastatin 10 Mg/day to Ezetimibe/simvastatin 10/20 Mg/day Compared to Doubling the Dose of Atorvastatin in Hypercholesterolaemic Patients With Atherosclerosis or Coronary Heart Disease. Int J Clin Pract. 2005;59(12):1377-86. PubMed PMID: 16351668.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. AU - Barrios,V, AU - Amabile,N, AU - Paganelli,F, AU - Chen,J-W, AU - Allen,C, AU - Johnson-Levonas,A O, AU - Massaad,R, AU - Vandormael,K, PY - 2005/12/15/pubmed PY - 2006/5/26/medline PY - 2005/12/15/entrez SP - 1377 EP - 86 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 59 IS - 12 N2 - This randomised, double-blind study evaluated the efficacy and safety of ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg tablet compared to doubling the atorvastatin (ATV) dose in hypercholesterolaemic patients with atherosclerotic or coronary heart disease (CHD). The study group included 435 male and female CHD patients (aged >or=18 years) who had not achieved their low-density lipoprotein cholesterol (LDL-C) goal of <2.50 mmol/l while on a stable dose of ATV 10 mg for >or=6 weeks. After a 1-week diet/stabilisation period, patients with LDL-C >or=2.50 mmol/l and <or=4.20 mmol/l were randomised (1:1) to EZE/SIMVA 10/20 mg/day (n = 221) or ATV 20 mg/day (n = 214) for 6 weeks. The primary efficacy objective was to determine the per cent reduction from baseline in LDL-C at week 6. EZE/SIMVA 10/20 mg produced significantly greater mean per cent changes from baseline in LDL-C compared with ATV 20 mg (-32.8 vs. -20.3%; p </= 0.001). A significantly greater proportion of patients achieved an LDL-C goal <2.50 mmol/l with EZE/SIMVA than ATV (77.9 vs. 51.9%; p <or= 0.001). Significant improvements in total cholesterol (-20.3 vs. -13.0%), non-high-density lipoprotein cholesterol (non-HDL-C) (-27.9 vs. -17.0%), apolipoprotein B (-23.4 vs. -14.7%) and HDL-C (1.8 vs. -0.4%) were observed after switching to EZE/SIMVA 10/20 mg for 6 weeks (p < 0.05 for all parameters). EZE/SIMVA 10/20 mg was generally well tolerated, with an overall safety profile similar to that of ATV 20 mg. EZE/SIMVA 10/20 mg produced superior lipid-altering efficacy by dual inhibition of cholesterol synthesis and intestinal absorption compared with doubling the dose of ATV from 10 to 20 mg. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/16351668/Lipid_altering_efficacy_of_switching_from_atorvastatin_10_mg/day_to_ezetimibe/simvastatin_10/20_mg/day_compared_to_doubling_the_dose_of_atorvastatin_in_hypercholesterolaemic_patients_with_atherosclerosis_or_coronary_heart_disease_ L2 - https://doi.org/10.1111/j.1368-5031.2005.00714.x DB - PRIME DP - Unbound Medicine ER -